Experienced in Li-Fraumeni Syndrome

Dr. Jay C. Andersen

Oncology
12123 Southwest 69th Avenue, 
Tigard, OR 
Accepting New Patients
Offers Telehealth
Experienced in Li-Fraumeni Syndrome
12123 Southwest 69th Avenue, 
Tigard, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jay Andersen is an Oncologist in Tigard, Oregon. Dr. Andersen is rated as an Experienced provider by MediFind in the treatment of Li-Fraumeni Syndrome. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, HER-2 Positive Breast Cancer, and Inflammatory Breast Cancer. Dr. Andersen is currently accepting new patients.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in OR
Hospital Affiliations
Legacy Meridian Park Medical Center
Providence Willamette Falls Medical Center
Providence St Vincent Medical Center
Providence Portland Medical Center
Legacy Good Samaritan Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

12123 Southwest 69th Avenue, Tigard, OR 97223

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Drug
Study Drug: ARX788
Study Phase: Phase 2
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
Enrollment Status: Completed
Publish Date: September 30, 2025
Intervention Type: Drug
Study Drugs: tucatinib, trastuzumab deruxtecan
Study Phase: Phase 2
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Sacituzumab Govitecan-hziy
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 3
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

1 Total Publications

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.
Journal: Therapeutic advances in medical oncology
Published: October 23, 2024
Similar Doctors
Experienced in Li-Fraumeni Syndrome
Dr. Erin A. Salinas
Oncology
Experienced in Li-Fraumeni Syndrome
Dr. Erin A. Salinas
Oncology
265 North Broadway, 
Portland, OR 
 (8.4 miles away)
503-280-1223
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erin Salinas is an Oncologist in Portland, Oregon. Dr. Salinas is rated as a Distinguished provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Endometrial Stromal Sarcoma, and Malignant Mixed Mullerian Tumor. Dr. Salinas is currently accepting new patients.

Experienced in Li-Fraumeni Syndrome
Dr. Julia E. Fehniger
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Experienced in Li-Fraumeni Syndrome
Dr. Julia E. Fehniger
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

Legacy Clinics LLC

1130 Nw 22nd Ave, Suite 110, 
Portland, OR 
 (7.2 miles away)
503-413-8654
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Julia Fehniger is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Portland, Oregon. Dr. Fehniger is rated as an Advanced provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, and Bladder Reconstruction. Dr. Fehniger is currently accepting new patients.

Experienced in Li-Fraumeni Syndrome
Dr. Nora J. Bucher
Hematology Oncology | Hematology | Oncology
Experienced in Li-Fraumeni Syndrome
Dr. Nora J. Bucher
Hematology Oncology | Hematology | Oncology

Northwest Cancer Specialists PC

12123 Sw 69th Ave, 
Tigard, OR 
 (0.1 miles away)
971-708-7600
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Nora Bucher is a Hematologist Oncology specialist and a Hematologist in Tigard, Oregon. Dr. Bucher is rated as an Advanced provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Breast Cancer, Hemochromatosis, Paget Disease of the Breast, and HER-2 Positive Breast Cancer. Dr. Bucher is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Andersen's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 130 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile